| abstract |
The present invention is directed to a molecule comprising a polypeptide having substantial homology with a CTL epitope selected from the group consisting of ADLMGYIPLV (Core<SUB>131-140</SUB>; SEQ ID NO:1), LLALLSCLTV (Core<SUB>178-187</SUB>; SEQ ID NO:2), QLRRHIDLLV (SEQ ID NO:55), LLCPAGHAV (NS3<SUB>1169-1177</SUB>; SEQ ID NO:26), KLVALGINAV (NS3<SUB>1406-1415</SUB>; SEQ ID NO:28), SLMAFTAAV (NS4<SUB>1789-1797</SUB>; SEQ ID NO:34), LLFNILGGWV (NS4<SUB>1807-1816</SUB>; SEQ ID NO:35), and ILDSFDPLV (NS5<SUB>2252-2260</SUB>; SEQ ID NO:42). Such molecules are used for the treatment and prevention of acute or chronic HCV hepatitis; suitable pharmaceutical compositions and methods using such compositions are disclosed. |